These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31507079)

  • 21. A predictive probability design for phase II cancer clinical trials.
    Lee JJ; Liu DD
    Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.
    Goffin JR; Pond GR; Tu D
    BMC Med Res Methodol; 2011 Jun; 11():95. PubMed ID: 21693051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.
    Iasonos A; Sabbatini P; Spriggs DR; Aghajanian CA; O'Cearbhaill RE; Hensley ML; Thaler HT
    Int J Gynecol Cancer; 2012 Jan; 22(1):63-9. PubMed ID: 22080877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
    Chen CM; Chi Y; Chang HM
    J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.
    Mander AP; Thompson SG
    Contemp Clin Trials; 2010 Nov; 31(6):572-8. PubMed ID: 20678585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
    Shi H; Yin G
    Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
    Polley MY; Cheung YK
    Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials.
    Song G; Ivanova A
    J Biopharm Stat; 2015; 25(6):1206-14. PubMed ID: 26383917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal two-stage design of single arm Phase II clinical trials based on median event time test.
    Park Y
    PLoS One; 2021; 16(2):e0246448. PubMed ID: 33556130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Bayesian early stopping boundaries for phase II clinical trials.
    Jiang L; Yan F; Thall PF; Huang X
    Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curtailed two-stage matched pairs design in double-arm Phase II clinical trials.
    Carsten C; Chen P
    J Biopharm Stat; 2016; 26(5):816-22. PubMed ID: 26368314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents.
    Jamal R; Goodwin RA; Tu D; Walsh W; Lacombe D; Eisenhauer EA
    Ann Oncol; 2013 Jul; 24(7):1936-1942. PubMed ID: 23553058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.
    Mander AP; Wason JM; Sweeting MJ; Thompson SG
    Pharm Stat; 2012; 11(2):91-6. PubMed ID: 22232071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial design with growth modulation index as the primary endpoint.
    Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
    Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
    Kocherginsky M; Cohen EE; Karrison T
    J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.